(Albany, USA) DelveInsight’s “KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The KRAS Inhibitors market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted KRAS Inhibitors market size from 2020 to 2034, segmented by seven major markets. The Report also covers current KRAS Inhibitors treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the KRAS Inhibitors market.
Request for a Free Sample Report @ KRAS Inhibitors Market Forecast
Some facts of the KRAS Inhibitors Market Report are:
According to DelveInsight, KRAS Inhibitors market size is expected to grow at a decent CAGR by 2034.
Leading KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
Key KRAS Inhibitors Therapies expected to launch in the market are LUMAKRAS/LUMYKRAS (sotorasib), KRAZATI (adagrasib), JDQ443, Divarasib, and others.
In April 2023,BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
In May 2023, Mirati Therapeutics announced Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients.
In Jan 2023, Pfizer and Array BioPharma announced the Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
KRAS Inhibitors Overview
KRAS inhibitors are a type of targeted therapy designed to block the activity of the KRAS gene, which plays a crucial role in many cancers. The KRAS gene belongs to a family of genes known as RAS genes, and it regulates cell division and growth. Mutations in the KRAS gene can cause cells to grow and divide uncontrollably, leading to the development of cancer.
Historically, KRAS mutations have been challenging to target with conventional therapies, making KRAS-driven cancers difficult to treat. However, significant progress has been made in recent years in developing KRAS inhibitors that can effectively block the abnormal activity of mutated KRAS proteins. These inhibitors work by specifically targeting the altered KRAS protein, aiming to inhibit its signaling pathways and disrupt cancer cell growth.
Learn more about KRAS Inhibitors treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ KRAS Inhibitor Treatment Market
KRAS Inhibitors Market
The KRAS Inhibitors market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted KRAS Inhibitors market trends by analyzing the impact of current KRAS Inhibitors therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the KRAS Inhibitors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated KRAS Inhibitors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the KRAS Inhibitors market in 7MM is expected to witness a major change in the study period 2020-2034.
KRAS Inhibitors Epidemiology
The KRAS Inhibitors epidemiology section provides insights into the historical and current KRAS Inhibitors patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the KRAS Inhibitors market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about KRAS Inhibitors Epidemiology @ KRAS Inhibitors Market Dynamics
KRAS Inhibitors Drugs Uptake
This section focuses on the uptake rate of the potential KRAS Inhibitors drugs recently launched in the KRAS Inhibitors market or expected to be launched in 2020-2034. The analysis covers the KRAS Inhibitors market uptake by drugs, patient uptake by therapies, and sales of each drug.
KRAS Inhibitors Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on KRAS Inhibitors market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
KRAS Inhibitors Pipeline Development Activities
The KRAS Inhibitors report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses KRAS Inhibitors key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the KRAS Inhibitors pipeline development activities @ KRAS Inhibitors Therapies and Drugs
KRAS Inhibitors Therapeutics Assessment
Major key companies are working proactively in the KRAS Inhibitors Therapeutics market to develop novel therapies which will drive the KRAS Inhibitors treatment markets in the upcoming years are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
Learn more about the emerging KRAS Inhibitors therapies & key companies @ KRAS Inhibitors Clinical Trials and FDA Approvals
KRAS Inhibitors Report Key Insights
1. KRAS Inhibitors Patient Population
2. KRAS Inhibitors Market Size and Trends
3. Key Cross Competition in the KRAS Inhibitors Market
4. KRAS Inhibitors Market Dynamics (Key Drivers and Barriers)
5. KRAS Inhibitors Market Opportunities
6. KRAS Inhibitors Therapeutic Approaches
7. KRAS Inhibitors Pipeline Analysis
8. KRAS Inhibitors Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the KRAS Inhibitors Market
Table of Contents
1. Key Insights
2. Executive Summary
3. KRAS Inhibitors Competitive Intelligence Analysis
4. KRAS Inhibitors Market Overview at a Glance
5. KRAS Inhibitors Disease Background and Overview
6. KRAS Inhibitors Patient Journey
7. KRAS Inhibitors Epidemiology and Patient Population
8. KRAS Inhibitors Treatment Algorithm, Current Treatment, and Medical Practices
9. KRAS Inhibitors Unmet Needs
10. Key Endpoints of KRAS Inhibitors Treatment
11. KRAS Inhibitors Marketed Products
12. KRAS Inhibitors Emerging Therapies
13. KRAS Inhibitors Seven Major Market Analysis
14. Attribute Analysis
15. KRAS Inhibitors Market Outlook (7 major markets)
16. KRAS Inhibitors Access and Reimbursement Overview
17. KOL Views on the KRAS Inhibitors Market
18. KRAS Inhibitors Market Drivers
19. KRAS Inhibitors Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
